Zacks Investment Research upgraded shares of FEMALE HEALTH (FHCO) from NEUTRAL to OUTPERFORM on December 17, 2012, with a target price of $7.70.
The Female Health Company manufactures, markets and sells the Female Condom, the only FDA-approved product under a woman's control which can prevent unintended pregnancy and sexually transmitted diseases, including HIV/AIDS. It is the only HIV/AIDS product specifically developed and approved by regulatory agencies in the U.S., the European Union, Japan and The People's Republic of China, among others, since the epidemic began about twenty years ago for the prevention of the transmission of HIV/AIDS through sexual contact.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on FEMALE HEALTH (FHCO),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment